Contains Nonbinding Recommendations

Draft Guidance on Ribociclib Succinate

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredient: Ribociclib succinate
Dosage Form; Route: Tablet; oral
Recommended Studies: Two studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: EQ 200 mg BASE
   Subjects: Females of non-child bearing potential, general population
   Additional comments: The tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). Due to potential for impairment of male fertility and embryo-fetal toxicity, studies should not be conducted in males and females of child bearing potential.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: EQ 200 mg BASE
   Subjects: Females of non-child bearing potential, general population
   Additional comments: See above

Analytes to measure (in appropriate biological fluid): Ribociclib in plasma

Bioequivalence based on (90% CI): Ribociclib

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

Recommended Nov 2018